Background Clinical guidelines have supported outpatient treatment of low‐risk pulmonary
embolism (PE) since 2014, but adoption of this practice has been slow. Direct oral …

Cancer patients develop a hypercoagulable state with a four-to seven-fold higher
thromboembolic risk compared to non-cancer patients. Thromboembolic events can precede …

Background Current guidelines recommend a risk-adjusted treatment strategy for the
management of acute pulmonary embolism. This is a particular patient category for whom …

Pulmonary embolism (PE) affects over 300,000 individuals each year in the United States
and is associated with substantial morbidity and mortality. Improvements in the diagnostic …

Much excitement has been generated with the approval of idarucizumab, a humanized
monoclonal antigen‐binding antibody fragment that is capable of reversing the …

Los anticoagulantes orales clásicos del tipo cumarinas han estado disponibles para uso
clínico por más de medio siglo. Tienen gran eficacia para tratar o prevenir trombosis y …

Background To evaluate the effect of oral anticoagulants (OACs) therapy, including vitamin
K antagonist (VKA) and direct oral anticoagulants (DOAC) in patients with pulmonary …

Anticoagulation therapy is the cornerstone of treatment in acute vein thrombosis (DVT) and it
aims to reduce symptoms, thrombus extension, DVT recurrences, and mortality. The …

Background Venous thromboembolism (VTE) is a common cause of morbidity and mortality
in cancer patients. Until recently, guidelines recommended the use of low-molecular weight …

Objective: The objective of this review is to examine the management strategies for
pulmonary embolism (PE) with an emphasis of the role of direct oral anticoagulants …